Genmab A/S announced a partnership with Anthropic to advance and enhance the company's research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab's clinical development priorities. Genmab's teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab's clinical programs as they progress toward key regulatory mi lestones.
Genmab continues to advance several late-stage investigational antibody medicines across solid tumors and hematological malignancies and is investing in digital and AI-driven capabilities that will further support the expansion and execution of its growing pipeline.
